Relaxin ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	2

51. Scleroderma

---

Clinical trials : 525 /  Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00704665 (ClinicalTrials.gov)	December 1998	23/6/2008	Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma	A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma	Systemic Sclerosis	Drug: Relaxin	University of Medicine and Dentistry of New Jersey	University of California, Los Angeles;Boston University;University of Chicago;University of Connecticut Health Center;Johns Hopkins University;University of Pittsburgh;Medical University of South Carolina;Stanford University;Georgetown University;University of California, San Diego;Wayne State University;University of Colorado, Denver;Medical College of Wisconsin	Completed	18 Years	70 Years	Both	231	Phase 3	NULL
2	NCT00004380 (ClinicalTrials.gov)	December 1991	18/10/1999	Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis		Systemic Sclerosis	Drug: relaxin	National Center for Research Resources (NCRR)	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Stanford University	Completed	N/A	N/A	Both	1	Phase 2	NULL